Haematological malignancies were previously thought to be driven solely by genetic or
epigenetic lesions within haematopoietic cells. However, the niches that maintain and …

Before it was molecularly cloned in 1994, acute-phase response factor or signal transducer
and activator of transcription (STAT) 3 was the focus of intense research into understanding …

Genetic and functional studies underscore the central role of JAK/STAT signaling in
myeloproliferative neoplasms (MPNs). However, the mechanisms that mediate …

Clonal alterations in hematopoietic cells occur during aging and are often associated with
the establishment of a subclinical inflammatory environment. Several age-related conditions …

Abstract Interleukin-1β (IL-1β) is a master regulator of inflammation. Increased activity of IL-
1β has been implicated in various pathological conditions including myeloproliferative …

Abstract Background The Janus kinase (JAK) and signal transduction and activation of
transcription (STAT) signaling pathway is an attractive target in multiple cancers. Activation …

Myeloproliferative Neoplasms | New England Journal of Medicine Skip to main content The
New England Journal of Medicine homepage Advanced Search SEARCH SPECIALTIES …

Myeloid neoplasms, including acute myeloid leukemia (AML), myeloproliferative neoplasms
(MPNs), and myelodysplastic syndromes (MDS), feature clonal dominance and remodeling …

Myeloproliferative neoplasms are associated with increased risk for thrombotic
complications. These conditions most commonly involve somatic mutations in genes that …

Fedratinib is an oral, selective Janus kinase 2 (JAK2) inhibitor. The phase II JAKARTA2
study assessed fedratinib in patients with intermediate‐or high‐risk myelofibrosis (MF) who …